The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial loss i